News & Articles
Written by the physicians who build eNavvi. What is shifting in prescribing, access and cost — and what we ship in response.
6 articles
Perimenopause Prescribing in 2026: Why Compounding Is the Missing Piece
Estrogen-based hormone replacement therapy prescribing has more than doubled since 2018. The most dramatic increase is in the perimenopause population: as of February 2026, 1 in 20 women aged 45–54…
Read The Article
Women’s HRT in 2026: The Estrogen Shortage, the Access Gap, and Where Compounding Fits
Hormone replacement therapy prescriptions for women aged 50–65 have increased 86% since 2021. The FDA removed boxed warnings on HRT products last year, citing evolving evidence on safety and newer…
Read more
A Prescriber’s Guide to Compounded HRT: Formulations, Dosing, and How to Order
Hormone replacement therapy compounding represents the single largest category in compounding pharmacy, accounting for approximately 36% of all compounding prescriptions nationally according to the…
Read more
Digital Compounding Prescriptions in 2025: What Physicians Need to Know About Access, Safety, and Cost Transparency
Executive summary Compounded medications continue to play an important role in patient care when FDA-approved products are unavailable, contraindicated, or insufficient for individualized needs. Yet…
Read more
PT-141 (Bremelanotide Acetate): Clinical Overview, Uses, and Compounded Formulations
Introduction PT-141, chemically known as Bremelanotide Acetate, is a synthetic peptide analog of α-melanocyte-stimulating hormone (α-MSH). It acts primarily as a melanocortin receptor agonist,…
Read more
Birth Control Options
Birth control is the process of preventing pregnancy, in a multitude of ways with each one possessing a number of advantages and disadvantages. It can be employed by both men & women and common…
Read moreverified prescribers already on eNavvi — every one identity-proofed and license-checked.
